Cargando…

The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment

The development of cancer causes disruption of anti-tumor immunity required for surveillance and elimination of tumor cells. Immunotherapeutic strategies aim for the restoration or establishment of these anti-tumor immune responses. Cancer immunotherapies include immune checkpoint inhibitors (ICIs),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uche, Ifeanyi Kingsley, Kousoulas, Konstantin G., Rider, Paul J. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310320/ https://www.ncbi.nlm.nih.gov/pubmed/34206677 http://dx.doi.org/10.3390/v13071200

Ejemplares similares

Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model
por: Uche, Ifeanyi Kingsley, et al.
Publicado: (2021)

Utility of a Recombinant HSV-1 Vaccine Vector for Personalized Cancer Vaccines
por: Uche, Ifeanyi Kingsley, et al.
Publicado: (2022)

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice
por: Israyelyan, Anna, et al.
Publicado: (2008)

Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018)

Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis
por: Naidu, Shan K., et al.
Publicado: (2020)

The Oncolytic herpes simplex virus type-1 (HSV-1) vaccine strain VC2 causes intratumor infiltration of functionally active T cells and inhibition of tumor metastasis and pro-tumor genes VEGF and PDL1 expression in the 4T1/Balb/c mouse model of stage four breast cancer
por: Nabi, Rafiq, et al.
Publicado: (2023)

HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy
por: Li, H, et al.
Publicado: (2013)

Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors
por: Hong, Bangxing, et al.
Publicado: (2022)

Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses—Clearance and Biodistribution in Naïve and HSV-Preimmune Mice
por: Vannini, Andrea, et al.
Publicado: (2023)

Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
por: Thomas, Suzanne, et al.
Publicado: (2019)

Construction of Various γ34.5 Deleted Fluorescent-Expressing Oncolytic herpes Simplex type 1 (oHSV) for Generation and Isolation of HSV-Based Vectors
por: Abdoli, Shahriyar, et al.
Publicado: (2017)

Effect of Complexes of Cobalt With Aminoacids on the Replication of Herpes Simplex Virus Type 1 (HSV-1)
por: Varadinova, T., et al.
Publicado: (1996)

Herpes Simplex Virus-Type1 (HSV-1) Impairs DNA Repair in Cortical Neurons
por: De Chiara, Giovanna, et al.
Publicado: (2016)

Herpes Simplex Virus Type 1 (HSV-1) Meningoencephalitis in an Immunocompetent Young Adolescent Female
por: Garcia, Monica, et al.
Publicado: (2022)

Stability and anti-tumor effect of oncolytic herpes simplex virus type 2
por: Wang, Yang, et al.
Publicado: (2018)

Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers
por: Scanlan, Hayle, et al.
Publicado: (2022)

45724 VC2 Oncolytic Virotherapy Induces Robust Systemic Anti-Tumor Immunity and Increases Survival in an Immunocompetent B16F10-derived Mouse Melanoma Model
por: Uche, Ifeanyi Kingsley, et al.
Publicado: (2021)

Chimeric HCMV/HSV-1 and Δγ(1)34.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory()()
por: Ghonime, Mohammed G., et al.
Publicado: (2017)

Pneumomediastinum and Pneumothorax Associated with Herpes Simplex Virus (HSV) Pneumonia
por: López-Rivera, Fermín, et al.
Publicado: (2018)

Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
por: Aldrak, Norah, et al.
Publicado: (2021)

Oncolytic Herpes Simplex Virus Immunotherapy for Brain Tumors: Current Pitfalls and Emerging Strategies to Overcome Therapeutic Resistance
por: Totsch, Stacie K., et al.
Publicado: (2019)

Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses
por: Stanfield, Brent A., et al.
Publicado: (2021)

Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models
por: Braidwood, Lynne, et al.
Publicado: (2014)

Molecular and biological characterization of a herpes simplex virus type 1 (HSV-1) neuroinvasiveness gene
Publicado: (1990)

Effect of Copper Acyclovir Complexes on Herpes Simplex Virus Type 1 and Type 2 (HSV-1, HSV-2) Infection in Cultured Cells
por: Panteva, M., et al.
Publicado: (1998)

Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA
por: Boscheinen, Jan B., et al.
Publicado: (2019)

Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion
por: Cockle, Julia V., et al.
Publicado: (2017)

1410. Neonatal Herpes Simplex Virus (HSV) Infection: Is It the Only Pathogen?
por: Dendi, Alvaro, et al.
Publicado: (2020)

Presage of oncolytic virotherapy for oral cancer with herpes simplex virus
por: Yura, Yoshiaki
Publicado: (2017)

The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment
por: Nguyen, Hong-My, et al.
Publicado: (2021)

Correction: Effect of Copper Acyclovir Complexes on Herpes Simplex Virus Type 1 and Type 2 (HSV-1, HSV-2) Infection in Cultured Cells
por: Panteva, M., et al.
Publicado: (1998)

39.3 CAN NEUROVIRAL INFECTIONS WITH HERPES SIMPLEX VIRUS, TYPE 1 (HSV-1) CONTRIBUTE TO RDOC?
por: Nimgaonkar, Vishwajit, et al.
Publicado: (2018)

Host Intrinsic and Innate Intracellular Immunity During Herpes Simplex Virus Type 1 (HSV-1) Infection
por: Alandijany, Thamir
Publicado: (2019)

Inactivation of the UL37 Deamidase Enhances Virus Replication and Spread of the HSV-1(VC2) Oncolytic Vaccine Strain and Secretion of GM-CSF
por: Clark, Carolyn M., et al.
Publicado: (2023)

Predicted Structure and Functions of the Prototypic Alphaherpesvirus Herpes Simplex Virus Type-1 UL37 Tegument Protein
por: Collantes, Therese Marie A., et al.
Publicado: (2022)

Comparative Evaluation of AmpliVue HSV 1+2 Assay with ELVIS Culture for Detecting Herpes Simplex Virus 1 (HSV-1) and HSV-2 in Clinical Specimens
por: Granato, Paul A., et al.
Publicado: (2015)

Herpes Simplex Virus (HSV-1) Encephalitis Mimicking Glioblastoma: Case Report and Review of the Literature
por: Cunha, Burke A., et al.
Publicado: (2014)

Herpes Simplex Virus Mistyping due to HSV-1 × HSV-2 Interspecies Recombination in Viral Gene Encoding Glycoprotein B
por: Casto, Amanda M., et al.
Publicado: (2020)

Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Pediatric Solid Tumors
por: Megison, Michael L., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vdtmon7tgig59i3tvaun6tuuvh